Loading
In KEYNOTE-204, PD-1 blockade beat the CD30 ADC head to head in relapsed Hodgkin lymphoma.
KEYNOTE-204, trial NCT02684292 sponsored by Merck and published in Lancet Oncology in 2021, showed that PD-1 blockade with pembrolizumab beats the CD30 antibody-drug conjugate brentuximab vedotin head to head in relapsed or refractory classical Hodgkin lymphoma. It randomised 304 patients and met its primary progression-free survival endpoint with a clear advantage, leading to approval in October 2020 for relapse after at least one line in adults and at least two in children. OnCo links it to Hodgkin lymphoma, pembrolizumab and brentuximab vedotin. Whether the two drugs are better used in sequence or in combination, and which should come first, is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Brentuximab vedotin, Hodgkin lymphoma, Immune checkpoint inhibitors.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma, Immune checkpoint inhibitors.